Polycystic Ovary Syndrome and Therapeutic Potential of Inositol Compounds
- Pp. 187-196 (10)A.K.M. Shamsuddin and Guang-Yu Yang
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among females. Although there is a diverse range of causes that are not entirely understood, recent studies indicate the potential role of myo-inositol in the pathophysiology of PCOS: i) insulin resistance in PCOS women can be attributed to a deficiency of myo-inositol’s intracellular metabolites, D-chiro-inositol (DCI) and inositol-phosphoglycan (IPG), mediators of insulin action; ii) PCOS patients have a higher urinary clearance of DCI; and iii) DCI functions as an intracellular messenger in mammalian oocytes, playing a role in the follicular milieu, meiotic resumption, and oocyte maturation. Recently, myo-inositol has been used in PCOS patients more and more as a natural insulin sensitizer and until today, there are more than 70 clinical trials on determining the effect of myo-inositol and/or DCI as insulin-sensitizing compound in PCOS women.